secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001193125-26-022559
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics exchanges 6.6M shares for pre-funded warrants with RA Capital and BVF
--------------------------------------------------------------------------------

- RA Capital exchanged 4,850,000 shares for a warrant to acquire 4,850,000 shares.
- BVF exchanged 1,750,000 shares for a warrant to acquire 1,750,000 shares.
- Post-exchange shares outstanding as of Jan 23, 2026: 51,007,874; warrants exercisable for 16,935,665 total shares.
- Warrants have $0.0001 exercise price, no expiration, and 4.99%/9.99% beneficial ownership blocker.
- Issued in reliance on Section 3(a)(9) exemption from registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526022559/0001193125-26-022559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526022559/fdmt-20260122.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-022559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer